Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chronic hepadnavirus infection is associated with
hepatocellular carcinoma
(
HCC
) in natural hosts such as humans, woodchucks, and Beechey ground squirrels. Several possible oncogenic mechanisms have been identified, including a potential role of the hepadnavirus x (hbx) gene, which transactivates transcription regulated by certain cis-acting sequences, e.g. regulatory sequences of the hepatitis B virus (HBV) and heterologous regulatory sequences of other viruses and cellular genes. The oncogenic potential of hbx is suggested by the observation of HCCs in hbx transgenic mice, the oncogenic transformation of cells expressing hbx in culture, and the transactivation of oncogenes c-myc and c-jun by hbx. Cis-activation of cellular oncogenes N-myc and c-myc by viral promoter insertion has been a common finding in woodchuck hepatitis virus (WHV)-associated HCCs of woodchucks. No such cis-activation of any cellular gene has been shown in virus-associated HCCs of ground squirrels or humans. Amplification and overexpression of the c-myc gene has been a common finding in HCCs of ground squirrels, and is rare in woodchuck or human HCCs. Point mutations in the
p53
gene and allelic deletion of
p53
have been common findings in human HCCs, but have not been found in HCCs in woodchucks and have been found rarely in ground squirrels. How each of these genetic changes in the different hosts contributes to
HCC
remains to be determined, but apparently different changes in different HCCs of hepadnavirus-infected hosts suggest that several separate genetic events may contribute to the development of
HCC
. These events may differ in each host, and some may not result from a direct virus-specific mechanism. Chronic hepadnavirus infection is often associated with chronic necroinflammatory liver disease and cirrhosis, a pathologic process common to several other risk factors for
HCC
. This suggests that this pathologic process (necroinflammatory disease) may be hepatocarcinogenic regardless of the inciting agent. Thus hepadnavirus infection may play an important role in the development of
HCC
by causing chronic hepatitis and
HCC
with the same mechanisms by which other risk factors for
HCC
cause chronic necroinflammatory liver disease and
HCC
.
...
PMID:Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. 819 85
The expression of the
p53 tumor suppressor
gene in ten human cell lines (nine cancers and one normal) was studied using reverse transcription, polymerase chain reaction (PCR) and direct sequencing. Using P53U and P53D primers for amplifying a 371-base pair (bp) target fragment spanning exons 7-10 of
p53
cDNA, normal-sized PCR products were amplified from 9 cell lines but not from the Hep3B
hepatocellular carcinoma
(
HCC
) cell line. An additional larger band (504 bp) was observed for the Molt-4 T-lymphoblastic leukemia cell line. Employing P531 and P53D primers which flank a 76-bp
p53
cDNA fragment, 76 bp as well as 209 bp products were generated by PCR of Molt-4 cDNA. Direct sequencing of the 504 bp and 209 bp bands confirmed the presence of a 133 bp insertion between exons 9 and 10 in the aberrant transcript. This insertion was homologous to a 130-bp sequence within the wild-type
p53
intron 9, except for 2 point mutations and 3 base insertions. Sequencing of P53U/P53D PCR products of Molt-4 genomic DNA revealed an 8 bp deletion just downstream to the 133 bp insertion, creating a novel donor splicing site within intron 9. This site, coupled with an inherent acceptor splicing site just upstream to the 133 bp insertion, suggests that the 133 bp stretch represents an alternative exon. The occurrence of a termination signal within this alternative transcript is predicted to culminate in a truncated p53 translational product. The sequences of the 371 bp PCR products of Molt-4, HT-1080, SiHa, CaSki, HeLa and MRC-5 cell lines corresponded with the wild-type
p53
cDNA. G-->T transversions at the third base of codon 249 of
p53
were detected in Mahlavu and PLC/PRF/5
HCC
lines, while a TAC to CAC mutation at codon 234 was observed in an allele of the Raji Burkitt lymphoma line.
...
PMID:Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. 822 26
We analyzed the status of retinoblastoma and
p53
genes in 10 human
hepatoma
cell lines. Polyclonal anti-peptide antibodies generated against peptides homologous to COOH-terminal and leucine-zipper domains of the retinoblastoma protein allowed us to identify two cell lines (Hep 3B and FOCUS) with abnormal expression. The same cell lines have both lacked
p53
expression. In contrast to the retinoblastoma gene, the expression of the
p53
gene was abnormal in six additional cell lines. Indeed, only the Hep G2 hepatoblastoma cell line (and its derivative Hep G2/2215) appeared to have normal
p53
and retinoblastoma gene expression. Our studies indicate that
p53
abnormalities are common but retinoblastoma gene aberrations are rare in human
hepatoma
cell lines.
...
PMID:Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. 822 13
In areas of the world where hepatitis B and aflatoxin ingestion are common, alterations of the
p53 tumor suppressor
gene have frequently been reported in
hepatocellular carcinoma
(
HCC
). In particular, G-to-T transversions at codon 249 of the
p53
gene have been consistently observed in hepatocellular carcinomas in China and sub-Saharan Africa. The goal of this study was to determine the frequency and relationship of
p53
gene alterations and hepatitis B in formalin-fixed, paraffin-embedded HCCs resected in the United States. Since immunoreactivity for
p53
correlates closely with the presence of missense mutations in the
p53
gene, we performed immunohistochemical staining with the monoclonal antibody PAb1801. Only seven of 37 cases (19%) demonstrated nuclear accumulation of
p53
gene product, in contrast to 10 of 20 cases (50%) of colon carcinoma metastatic to the liver. Staining was not observed in seven liver cell adenomas, 10 cases of focal nodular hyperplasia, or eight cases of cirrhosis. DNA was extracted from formalin-fixed paraffin sections for additional analysis with use of the polymerase chain reaction (PCR). G-to-T transversions of the third nucleotide of codon 249 were demonstrated in only four of 37 cases (11%), three of which had stained with PAb1801. Of 13 patients for whom there was information about a restriction fragment length polymorphism (RFLP) for BstUI within the fourth exon of the
p53
gene, allelic loss of
p53
was demonstrated in only two cases (15%), both of which stained with PAb1801. Because of previous reports specifically associating hepatitis B with
p53
mutations in
HCC
, we performed nested PCR for hepatitis B virus DNA. Five of 37 cases (14%) contained hepatitis B virus DNA, two of which stained diffusely for
p53
and three of which had codon 249 mutations. Our findings indicate that alterations in the
p53
gene, particularly at codon 249, are uncommon in HCCs in the United States, and when present are associated with hepatitis B. Since hepatitis B is infrequently associated with
HCC
in our patient population, the role of
p53
alterations in hepatocellular carcinogenesis may not be as significant as in other parts of the world where hepatitis B and aflatoxin are more prevalent.
...
PMID:Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. 823 31
Much evidences have showed a close relation between HBV infection and the development of primary
hepatocellular carcinoma
(PHC). Molecular genetic study showed loss of heterozygosity in PHC and that point mutation of
p53
exon 7 at codon 249 was important to PHC. But these changes of PHC associated with aflatoxin B1 and HBV were not apparent. Thirteen cases of PHC were examined to determine whether there were any relationship between HBxAg and
p53 protein
. HBV-DNA was integrated to PHC tissue in 9 of the 13 cases by southern blot; HBsAg, HBxAg or HBcAg was found in 8 by immunohistochemical staining. None had the point mutation of
p53
exon 7 at codon 229, 247 and 249 by PCR and restriction enzymes. Immunoprecipitation analyses were carried out to test whether anti-X antibody was capable of precipitating
p53
or anti-
p53
could immunoprecipitate HBxAg polypeptides from HBV infected tissue. Specific band was detected at 53,000 in 7 of the 13 cases as precipitating with anti-HBxAg and western blotting using anti-
p53
, and specific band was detected at 13,000, 17,000 or 28,000 in 6 of the 13 cases as precipitating with anti-
p53
and western blotting using anti-HBxAg. These results revealed that the binding of HBxAg to
p53
may be analogous to that observed in tumor antigen encoded from selected papovaviruses, and adenoviruses, and may be a crucial step in the development of PHC among most HBV infected patients.
...
PMID:[Hepatitis B X antigen binding to p53 protein in the pathogenesis of primary hepatocellular carcinoma]. 825 98
Hepatocellular carcinoma
samples obtained from 59 patients at surgical resection were examined for mutations of the third base at codon 249 of the
p53
gene, using the polymerase chain reaction and oligonucleotide hybridization techniques. This point mutation, which is frequently observed in
HCC
cases from Southern Africa and Quidong in China, was not recognized in either 60 hepatocellular carcinomas or 53 noncancerous liver tissue samples from Japan. Thirty-four of 45 patients (75.6%) were positive for the hepatitis C virus, which was a higher rate than that for hepatitis B virus infection (9 of 55; 16.4%). The exposure to aflatoxin B1 was not considered to be remarkable. These results suggest that the point mutation of the third base at codon 249 is not common in Japanese patients, and it is suggested that numerous other factors affect the mutation of the
p53
gene and the development of
hepatocellular carcinoma
.
...
PMID:The mutation of codon 249 in the p53 gene is not specific in Japanese hepatocellular carcinoma. 825 41
Hepatocellular carcinoma
(
HCC
) accumulates a mutation of the
p53
gene with a common substitution of nucleotide in a particular site. It is hypothesized that infection of hepatitis B virus (HBV) or exposure to aflatoxins could induce it. In Japan, the concentration of aflatoxins in the environment is low; however, infection of HBV and/or hepatitis C virus (HCV) is frequently seen in patients with
HCC
. The purpose of our studies was to determine whether these hepatoviral factors influence
p53
alterations. In our results,
p53
abnormalities, which were composed of loss of heterozygosity (LOH) and/or point mutation, were shown in 39% of patients. We postulated that they occurred at late stages in tumor growth based on the following two results. LOH analysis on
p53
showed that most of the tumor nodule consisted of two phenotypes, LOH and non-LOH cancer cells. The
p53
abnormalities correlated with the grade of cancer cell atypia which advanced with tumor growth. HBV and HCV infections were identified by polymerase chain reaction using DNA extracted from cancerous and noncancerous regions of the liver. By these methods, the patients who had been infected with either HBV or HCV showed an incidence of
p53
abnormalities (45%) higher than those infected by neither (13%). However, the detection rate of these viruses was lower in the
HCC
region (33%) than that in the noncancerous region (56%) in cases with mutated
p53
. The low rate of HCV detection (22%) in the
HCC
region with altered
p53
was attributable to these different viral detection rates. There was a difference in pattern of
p53
mutational changes in patients depending upon whether they were infected by HBV or by HCV. Two of three HBV-infected patients had a transversional change of nucleotide at the G:C site to T:A. However, in cases with HCV, four of eight patients had a transitional change of nucleotide of
p53
. These results showed that HBV and HCV infections affect carcinogenic pathways causing
p53
abnormalities independently.
...
PMID:p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. 826 44
Mutations in the
p53 tumor suppressor
gene are commonly found in the major human cancers and the mutational spectrum in some cancer types is consistent with the genotoxic effects of the associated environmental risk factors. Thus far there is little information on
p53
mutations in cancers of factory workers with a history of carcinogen exposure in the workplace. Occupational exposure to vinyl chloride causes liver angiosarcomas (ASL) and also increases the risk of several other cancers. Loss of
p53
function in osteo- and fibrosarcomas can occur by two different mechanisms,
p53
mutation and amplification of the MDM2 gene. We examined tumors from five vinyl chloride-exposed patients, four with ASL and one with
hepatocellular carcinoma
(
HCC
), for evidence of MDM2 proto-oncogene amplification or
p53
mutation in exons 5-8. Amplification of MDM2 was not found, but in two of the angiosarcomas an A:T to T:A missense mutation was detected.
p53
sequence analysis of vinyl chloride associated cancers may provide valuable information on the relationship between carcinogen exposure and DNA damage in cancer-related genes.
...
PMID:p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. 829 34
The
tumor suppressor p53
exerts important protective functions towards DNA-damaging agents. Its inactivation by allelic deletions or point mutations within the
P53
gene as well as complex formation of wildtype
p53
with cellular or viral proteins is a common and crucial event in carcinogenesis. Mutations increase the half-life of the
p53 protein
allowing the immunohistochemical detection and anti-
p53
antibody formation. Distinct G to T point mutations in codon 249 leading to a substitution of the basic amino acid arginine by the neutral amino acid serine are responsible for the altered functionality of the mutant gene product and were originally identified in 8 of 16 Chinese and 5 of 10 African
HCC
patients. Both groups are frequently exposed to mycotoxin contaminations of their food. Today an average
P53
gene mutation rate of 25% is assumed for high-aflatoxin B1-exposure regions. This is double the rate observed in low-aflatoxin B1-exposure countries. Although many
HCC
patients displaying
P53
mutations also suffer from HBV infection, which itself can lead to rearrangements of
P53
coding regions or induce the synthesis of viral proteins possibly interacting with
p53
, the specific G to T transversion within codon 249 of the
P53
gene seems to directly reflect the extent of aflatoxin B1 exposure.
...
PMID:Point mutations of the P53 gene, human hepatocellular carcinoma and aflatoxins. 830 Oct 66
p53
mutations are a common genetic finding in
hepatocellular carcinoma
from areas of high aflatoxin exposure. Recent small studies have shown that
p53
gene mutations may be less common in areas with a low prevalence of
hepatocellular carcinoma
such as Great Britain. The protein product of mutant p53 can be detected immunohistochemically because of its longer half life in comparison with native protein. This study used a novel monoclonal antibody DO-7, raised against recombinant
p53
and effective in routinely processed biopsy specimen tissue, to detect the mutant protein in a series of 45 cases of
hepatocellular carcinoma
occurring in white subjects resident in the United Kingdom. Focal nuclear labelling was seen in four cases (9%); surrounding cirrhotic tissue in one of these was negative for
p53
expression. This study shows that
p53
mutations are a rare event in hepatocarcinogenesis in Great Britain, an area of low aflatoxin exposure, and supports the concept of geographical variations in the cause and pathogenesis of
hepatocellular carcinoma
.
...
PMID:Expression of mutant p53 protein in hepatocellular carcinoma. 830 60
<< Previous
1
2
3
4
5
6
7
8
9
10